Short Interest in Predictive Oncology Inc. (NASDAQ:POAI) Decreases By 63.5%

Predictive Oncology Inc. (NASDAQ:POAI) was the target of a large decrease in short interest in July. As of July 15th, there was short interest totalling 19,000 shares, a decrease of 63.5% from the June 30th total of 52,000 shares. Based on an average daily volume of 1,750,000 shares, the short-interest ratio is currently 0.0 days. Approximately 0.5% of the shares of the stock are short sold.

Hedge Funds Weigh In On Predictive Oncology

A hedge fund recently bought a new stake in Predictive Oncology stock. Carnegie Mellon University acquired a new position in Predictive Oncology Inc. (NASDAQ:POAI) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 10,358 shares of the medical instruments supplier’s stock, valued at approximately $34,000. Predictive Oncology comprises approximately 0.0% of Carnegie Mellon University’s holdings, making the stock its 5th biggest holding. Carnegie Mellon University owned about 0.26% of Predictive Oncology at the end of the most recent quarter. Hedge funds and other institutional investors own 9.04% of the company’s stock.

Predictive Oncology Stock Up 74.8 %

POAI traded up $0.80 during trading on Thursday, reaching $1.87. 160,532,057 shares of the company were exchanged, compared to its average volume of 1,946,369. The company’s 50-day moving average is $1.27 and its two-hundred day moving average is $2.07. The company has a market cap of $7.67 million, a price-to-earnings ratio of -0.52 and a beta of 1.15. Predictive Oncology has a 12-month low of $0.89 and a 12-month high of $5.94.

Predictive Oncology (NASDAQ:POAI) last announced its quarterly earnings data on Tuesday, May 14th. The medical instruments supplier reported ($1.04) EPS for the quarter. Predictive Oncology had a negative net margin of 754.13% and a negative return on equity of 151.51%. The firm had revenue of $0.42 million for the quarter.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.